Abstract Preview:
Introduction Depression and anxiety are prevalent psychological disorders that significantly affect physical,emotional, and social well-being, reducing quality of life and increasing medical costs. These issues are especiallychallenging for cancer survivors, complicating treatment management, affecting adherence, and potentiallyimpacting survival rates. Thus, this umbrella review aimed to evaluate the global prevalence of pain, depression, andanxiety, as well as their determinants among cancer patients.Method An exhaustive umbrella review was conducted to systematically assess the prevalence and determinants ofpain, depression, and anxiety among cancer survivors worldwide by analyzing systematic reviews and meta-analyses.The review involved a thorough search of multiple databases and included studies published in English up to July2024 that reported on these symptoms. The process involved screening and selecting studies based on specificcriteria, assessing the risk of bias using the AMSTAR tool, and analyzing data with statistical methods to determineoverall prevalence and identify predictors. This comprehensive approach aimed to provide a detailed understandingof these psychological issues in cancer survivors and guide future research and interventions.Result The global summary prevalence of depression among cancer survivors was 33.16% (95% CI 27.59–38.74),while anxiety had a prevalence of 30.55% (95% CI 24.04–37.06). Pain prevalence after treatment was 39.77% (95%CI 31.84–47.70). Before treatment, 65.22% (95% CI 62.86–67.57) of cancer patients reported pain, which persistedin 51.34% (95% CI 40.01–62.67) during treatment. The analysis also found that during the COVID-19 pandemic,depression and anxiety rates among cancer patients were at their highest, with prevalences of 43.25% (95% CI41.25–45.26) and 52.93% (95% CI 50.91–54.96), respectively.Conclusion The umbrella review found that depression and anxiety prevalence among cancer survivors was33.16% and 30.55%, respectively, with significantly higher rates during COVID-19 at 43.25% and 52.93%. Key factorscontributing to depression included poor social support, advanced cancer stage, and inadequate sleep, while anxietywas significantly linked to advanced cancer stage and poor sleep quality.
Clinical trial number Not applicable.Keywords Cancer, Oncology, Pain, Depression, Anxiety, Cancer survivors, Systematic review, Meta-analysis, Umbrellareview
Full Abstract:
Introduction Depression and anxiety are prevalent psychological disorders that significantly affect physical,emotional, and social well-being, reducing quality of life and increasing medical costs. These issues are especiallychallenging for cancer survivors, complicating treatment management, affecting adherence, and potentiallyimpacting survival rates. Thus, this umbrella review aimed to evaluate the global prevalence of pain, depression, andanxiety, as well as their determinants among cancer patients.Method An exhaustive umbrella review was conducted to systematically assess the prevalence and determinants ofpain, depression, and anxiety among cancer survivors worldwide by analyzing systematic reviews and meta-analyses.The review involved a thorough search of multiple databases and included studies published in English up to July2024 that reported on these symptoms. The process involved screening and selecting studies based on specificcriteria, assessing the risk of bias using the AMSTAR tool, and analyzing data with statistical methods to determineoverall prevalence and identify predictors. This comprehensive approach aimed to provide a detailed understandingof these psychological issues in cancer survivors and guide future research and interventions.Result The global summary prevalence of depression among cancer survivors was 33.16% (95% CI 27.59–38.74),while anxiety had a prevalence of 30.55% (95% CI 24.04–37.06). Pain prevalence after treatment was 39.77% (95%CI 31.84–47.70). Before treatment, 65.22% (95% CI 62.86–67.57) of cancer patients reported pain, which persistedin 51.34% (95% CI 40.01–62.67) during treatment. The analysis also found that during the COVID-19 pandemic,depression and anxiety rates among cancer patients were at their highest, with prevalences of 43.25% (95% CI41.25–45.26) and 52.93% (95% CI 50.91–54.96), respectively.Conclusion The umbrella review found that depression and anxiety prevalence among cancer survivors was33.16% and 30.55%, respectively, with significantly higher rates during COVID-19 at 43.25% and 52.93%. Key factorscontributing to depression included poor social support, advanced cancer stage, and inadequate sleep, while anxietywas significantly linked to advanced cancer stage and poor sleep quality.
Clinical trial number Not applicable.Keywords Cancer, Oncology, Pain, Depression, Anxiety, Cancer survivors, Systematic review, Meta-analysis, Umbrellareview